Β-lactam allergy: Difference between revisions

From IDWiki
Β-lactam allergy
()
()
Line 1: Line 1:
{{DISPLAYTITLE:β-lactam allergy}}
{{DISPLAYTITLE:β-lactam allergy}}

==Hypersensitivity Reactions==

*'''Type I (IgE-mediated)'''
**Anaphylaxis
**Itchy rash
**Penicillins '''should be avoided'''
*'''Type II (IgG-mediated)'''
**Non-itchy rash
**Rash will improve if treatment continues, '''no need to avoid''' penicillins
*'''Type IV (cell-mediated)'''
**Toxic epidermal necrolysis
**Stevens-Johnson syndrome
**Penicillins '''should be avoided'''


==Cross-Reactivity==
==Cross-Reactivity==


*The following applies to '''immediate, IgE-mediated''' hypersensitivity reactions
*Cross-reactivity between [[penicillins]] and [[cephalosporins]] is mediated by homology of the R1 side chains, referring to the C6 side chain in [[penicillins]] or the C7 side chain in [[cephalosporins]]
*Cross-reactivity between [[penicillins]] and [[cephalosporins]] is mediated by homology of the R1 side chains, referring to the C6 side chain in [[penicillins]] or the C7 side chain in [[cephalosporins]]
*Cross-reactivity within [[cephalosporins]] is mediated both by homology of the R1 side chains and also R2 side chains, referring to the C3 side chain
*Cross-reactivity within [[cephalosporins]] is mediated both by homology of the R1 side chains and also R2 side chains, referring to the C3 side chain
*There is very low (~2%) cross-reactivity between penicillin allergy and [[carbapenems]][[CiteRef::kula2014a]]


{| class="wikitable"
{| class="wikitable"
Line 265: Line 281:
*'''Group 6:''' [[cefixime]]
*'''Group 6:''' [[cefixime]]
*'''Group 7:''' [[ceftazidime]]
*'''Group 7:''' [[ceftazidime]]

==Hypersensitivity Reactions==

*'''Type I (IgE-mediated)'''
**Anaphylaxis
**Itchy rash
**Penicillins '''should be avoided'''
*'''Type II (IgG-mediated)'''
**Non-itchy rash
**Rash will improve if treatment continues, '''no need to avoid''' penicillins
*'''Type IV (cell-mediated)'''
**Toxic epidermal necrolysis
**Stevens-Johnson syndrome
**Penicillins '''should be avoided'''


==Further Reading==
==Further Reading==

Revision as of 14:51, 16 September 2020


Hypersensitivity Reactions

  • Type I (IgE-mediated)
    • Anaphylaxis
    • Itchy rash
    • Penicillins should be avoided
  • Type II (IgG-mediated)
    • Non-itchy rash
    • Rash will improve if treatment continues, no need to avoid penicillins
  • Type IV (cell-mediated)
    • Toxic epidermal necrolysis
    • Stevens-Johnson syndrome
    • Penicillins should be avoided

Cross-Reactivity

  • The following applies to immediate, IgE-mediated hypersensitivity reactions
  • Cross-reactivity between penicillins and cephalosporins is mediated by homology of the R1 side chains, referring to the C6 side chain in penicillins or the C7 side chain in cephalosporins
  • Cross-reactivity within cephalosporins is mediated both by homology of the R1 side chains and also R2 side chains, referring to the C3 side chain
  • There is very low (~2%) cross-reactivity between penicillin allergy and carbapenems1
Antibiotic R1 R2
G1 G2 G3 G1 G2 G3 G4 G5 G6 G7
Penicillins
Penicillin X
Ampicillin X
Amoxicillin X
First-Generation Cephalosporins
Cefazolin
Cephalexin X X
Cefadroxil X X
Cephalothin X X
Second-Generation Cephalosporins
Cefotetan X
Cefoxitin X X
Cefuroxime X
Cefaclor X
Third-Generation Cephalosporins
Cefotaxime X X
Ceftriaxone X
Ceftazidime X
Cefixime X
Cefdinir
Fourth-Generation Cephalosporins and Higher
Cefipime X
Ceftaroline

R1 Side Chains (C6 and C7)

R2 Side Chains (C3)

Further Reading

  • Cross-reactivity in β-Lactam Allergy. J Allergy Clin Immunol Pract. 2018;6(1):72-81.e1. doi: 10.1016/j.jaip.2017.08.027
  • Cross-Reactivity to Cephalosporins and Carbapenems in Penicillin-Allergic Patients: Two Systematic Reviews and Meta-Analyses. J Allergy Clin Immunol Pract. 2019;7(8):2722-2738.e5. doi: 10.1016/j.jaip.2019.05.038

References

  1. ^  Brittany Kula, Gordana Djordjevic, Joan L. Robinson. A Systematic Review: Can One Prescribe Carbapenems to Patients With IgE-Mediated Allergy to Penicillins or Cephalosporins?. Clinical Infectious Diseases. 2014;59(8):1113-1122. doi:10.1093/cid/ciu587.